Biopharmaceutical company developing oncolytic virus-based immunotherapies for cancer treatment.
Genelux Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing cutting-edge oncolytic viral immunotherapies aimed at addressing aggressive and challenging-to-treat solid tumor conditions. At the forefront of its development pipeline is Olvi-Vec, a proprietary, engineered strain of the vaccinia virus designed specifically for combating ovarian cancer and non-small-cell lung cancer. The company's innovative approach harnesses the potential of viral therapy to target and destroy cancer cells while potentially stimulating an immune response against tumors.
In addition to Olvi-Vec, Genelux Corporation is actively pursuing the development of V2ACT Immunotherapy, which holds promise for treating pancreatic cancer, a notoriously difficult-to-treat malignancy with limited therapeutic options. The company also focuses on advancing V-VET1, a therapeutic candidate designed to combat both hematologic and solid cancers, highlighting its commitment to broadening the scope of effective cancer treatments.
Founded in 2001 and headquartered in Westlake Village, California, Genelux Corporation operates at the intersection of biopharmaceutical innovation and oncology, striving to redefine treatment paradigms through its pioneering viral immunotherapy platform. With a strong emphasis on research and development, the company continues to explore novel approaches to enhance therapeutic outcomes and improve the quality of life for cancer patients globally.
Driven by a mission to deliver transformative therapies, Genelux Corporation remains dedicated to leveraging its expertise in virology and immunotherapy to advance new treatment options for patients facing some of the most challenging forms of cancer.